Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 52 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

7 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

10 recruiting

Enrollment Performance

Analytics

Early Phase 1
13(28.3%)
N/A
12(26.1%)
Phase 2
9(19.6%)
Phase 3
6(13.0%)
Phase 1
5(10.9%)
Phase 4
1(2.2%)
46Total
Early Phase 1(13)
N/A(12)
Phase 2(9)
Phase 3(6)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (52)

Showing 20 of 52 trials
NCT07542379Early Phase 1Not Yet Recruiting

The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer

Role: collaborator

NCT07459283Early Phase 1Not Yet Recruiting

The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors

Role: collaborator

NCT07185308Not ApplicableNot Yet Recruiting

Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer

Role: collaborator

NCT07162779Not ApplicableEnrolling By Invitation

Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients

Role: lead

NCT03255694Phase 2Active Not Recruiting

A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

Role: collaborator

NCT07023848Early Phase 1Enrolling By Invitation

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

Role: lead

NCT07023861Early Phase 1Enrolling By Invitation

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

Role: lead

NCT02375620Phase 2Active Not Recruiting

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

Role: collaborator

NCT06874673Not ApplicableNot Yet Recruiting

Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis

Role: collaborator

NCT06824909Recruiting

Endoscopic Ultrasound-guided Fine-needle Aspiration of Solid Pancreatic Lesions With Rapid Staining of Cytological Smears Followed by Whole Slide Scanning and Artificial Intelligence Diagnosis: A Prospective, Multicenter Study.

Role: collaborator

NCT06809426Not ApplicableCompleted

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Role: lead

NCT06723665Not ApplicableEnrolling By Invitation

The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

Role: lead

NCT06684028Not ApplicableRecruiting

PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors

Role: lead

NCT06656624Phase 2Recruiting

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

Role: collaborator

NCT06527807Recruiting

Clinical Characteristics and Prognosis of Acute Stroke in Pregnancy and Puerperium

Role: collaborator

NCT06448975Not ApplicableRecruiting

An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease

Role: lead

NCT05268172Phase 1Recruiting

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Role: lead

NCT05669586Phase 2Recruiting

Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer

Role: lead

NCT06254690Phase 2Recruiting

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Role: collaborator

NCT05573373Phase 1Unknown

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

Role: lead